Multiple Myeloma
Key Points
Key Points
The estimated number of deaths from multiple myeloma in 2018 is 12,770, representing 2.1% of all cancer deaths.
Despite significant advances and improvements in overall survival, multiple myeloma remains incurable and additional treatments are needed.
The median survival is just over 5 years and most patients receive 4 or more different lines of therapy throughout their disease course.
Treatment
Treatm...
...ansplant Eligible
Patients should be referred to a tran...
...ronologic age and renal function shou...
...imen and number of cycles remain un...
...ont transplant should be offered to all transpla...
...ts associated with stem cell toxicity, such as me...
...l collection (sufficient for more than one SCT)...
...of minimal response required to proceed...
...se melphalan is the recommended condition...
...autologous SCT should not be routinely recomme...
...vage or delayed SCT may be used as consolidatio...
...logeneic transplant for multiple mye...
...therapy is not routinely recommended but...
...mide maintenance therapy should be routinely offe...
...tients intolerant of or unable to r...
...r high-risk patients, maintenance therapy with a...
...insufficient evidence to make modifica...
...nd depth of response should be assessed by IMWG...
...oal of initial therapy for transplant el...
...recommended that depth of response be asse...
...hole-body low dose CT scan has bee...
...ansplant Ineligible
...ent recommendations for patients with...
...treatment for patients with multiple myeloma w...
...rapies for patients with multiple my...
...s/patients should balance the potential improvemen...
...therapy should be offered over fixed...
...goal of initial therapy for transplant ineligible...
...se for all patients should be assessed by...
...here is insufficient evidence to support chan...
...tiation of therapy, one should define patient s...
...mended that patients be monitored closely w...
...psed Diseas...
...biochemically relapsed myeloma should be indi...
...y relapsed patients with symptoms due to myeloma...
...erapy should be administered on firs...
...ment of relapsed multiple myeloma may be cont...
...ior therapies should be taken into cons...
...ologous stem cell transplantation, if not received...
The risk status of the patients should be assesse...
...t risk assessment at the time of relapse sh...
...nt of other risk factors such as renal...
...atients with genetic high-risk disease...
...ith renal insufficiency, drugs should be m...
...n patients with plasma cell leukemia or ex...
...sed response criteria should be used fo...
...measurable parameters need to be followed i...
...sponses excluding marrow and imaging should...
...essment should be performed after...
Figure 1. Algorithm On Management of Patients...
...ugs Used in the Management of Patien...
...ble 2. Diagnostic Criteria for Active Mult...
...able 3. Revised International Staging Sys...
.... Comparison of Select Risk Prediction Models Rel...
...e 5. IMWG Response CriteriaHaving trouble...
...6. Estimated Cost of Drugs for Multip...